At the tender age of 6, Lucas Jemeljanova was diagnosed with diffuse intrinsic pontine glioma (DIPG), an exceedingly rare and aggressive form of brain tumor notorious for claiming the lives of 98 percent of its victims within five years.
In a twist of fate, Lucas became part of a clinical trial testing everolimus, a chemotherapy drug typically used for other cancers such as kidney, pancreas, breast, and brain tumors, but not previously proven effective against DIPG.
Under the care of his parents, Cedric and Olesja, Lucas participated in the BIOMEDE trial in France, where doctors administered everolimus. This drug operates by inhibiting mTOR, a protein crucial for cancer cell proliferation and blood vessel formation, effectively stunting tumor growth.
The medical team closely monitored Lucas's progress, hesitant to halt treatment until about a year and a half ago when it was discovered that Lucas had discontinued taking the medication on his own.
In an astonishing turn of events, Dr. Jacques Grill, the head of the brain tumor program at Gustave Roussy cancer center in Paris, witnessed through a series of MRI scans as Lucas's tumor completely vanished.
Although seven other children in the trial showed promising results as 'long responders,' Lucas stood out as the sole case where the tumor disappeared entirely. Dr. Grill attributes this remarkable outcome to an exceptionally rare mutation present in Lucas's tumor cells, rendering them uniquely sensitive to the drug.
DIPG, affecting around 300 children annually, typically manifests between the ages of five and nine, situated at the brain's base and spine's top. Its precise cause remains elusive, yet its impact on vital bodily functions, such as breathing and blood pressure regulation, is profound and devastating.
Symptoms of DIPG often manifest subtly initially, including eye movement issues, facial weakness, gait disturbances, and balance problems, as was the case with Lucas, who exhibited alarming signs like difficulty walking, urinary issues, fainting spells, and nosebleeds at the age of six.
In light of Lucas's extraordinary response to treatment, researchers are now diligently working to decipher the genetic intricacies of his tumor cells. By studying tumor organoids, artificially grown cell masses resembling organs, they aim to replicate Lucas's genetic anomalies, paving the way for targeted therapies capable of replicating the miraculous outcome witnessed in Lucas's case.
As Dr. Grill underscores, unlocking the secrets behind Lucas's unique recovery holds immense promise for future DIPG patients, offering hope for effective treatments where none existed before.
0 Comments